GenSight's long Lumevoq march goes on

22 July 2022
gensight_large

France’s GenSight Biologics (Euronext: SIGHT), a company focused on discovering and developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has not had an easy year.

The firm’s share price has dropped by nearly 55% so far in 2022 amid setbacks with its lead product candidate, lenadogene nolparvovec (GS010), which is in Phase III trials in Leber hereditary optic neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults.

"With even more confidence about the benefit we can deliver to patients, the GenSight team is working with full intensity to bring our therapy to patients"GenSight plans to sell the drug under the brand name Lumevoq but its attempts to bring it to market have stalled this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology